ProciseDx wins CE Mark for point-of-care tests

By staff writers

September 10, 2020 -- Nestlé Health Science subsidiary ProciseDx has received the European CE Mark for Procise IFX and Procise ADL, the company's infliximab and adalimumab point-of-care diagnostics.

Procise IFX and Procise ADL provide diagnostic data for therapeutic drug monitoring within five minutes of a finger-prick blood sample, the company noted. Both tests run on the ProciseDx system, which is about the size of a shoe box.

ProciseDx moves forward with CRP test
Nestlé Health Science subsidiary ProciseDx said that it has submitted a 510(k) application for its Procise point-of-care C-reactive protein (CRP) test...
Nestle's ProciseDx inks technology deal with Lumiphore
Nestlé Health Science subsidiary ProciseDx is set to use Lumiphore's metal luminescent reporter technology in a broad range of rapid point-of-care...

Copyright © 2020

Last Updated ls 9/21/2020 8:42:48 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current